|Day Low/High||0.53 / 0.58|
|52 Wk Low/High||0.48 / 1.40|
Fast Track designation highlights high unmet medical need in the treatment of Fabry disease
Data to be presented in an oral presentation and two poster presentations
Oral Presentation of Long Term Results from the Phase I/II Open-Label Extension Trial of PRX-102 for Fabry Disease
Concurrently the Company Completes Private Placement of $10 Million Convertible Notes
Multi-product facility to support the potential manufacturing of both pegunigalsidase alfa and taliglucerase alfa on a commercial scale
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.